|Bid||17.71 x 0|
|Ask||16.41 x 0|
|Day's Range||16.27 - 16.41|
|52 Week Range||12.65 - 16.57|
|Beta (3Y Monthly)||0.72|
|PE Ratio (TTM)||53.03|
|Forward Dividend & Yield||0.18 (1.28%)|
|1y Target Est||N/A|
ResMed today announced that Mick Farrell, chief executive officer, will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019, beginning at approximately 8:40 a.m.
.@ResMed study finds #CPAP adherence improved by remote monitoring, self-monitoring across 3 countries
Age, gender, and disease severity all impact long-term #CPAP adherence more than previously thought, according to a million-patient study shown at #ATS2019 #sleepapnea
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital SaaS solutions, today announced it has elected experienced business executive Jan De Witte to its board of directors. Mr. De Witte was appointed during ResMed’s regularly scheduled board meeting on May 16, 2019, to fill a newly created directorship, effective immediately.
Brightree® today announced plans for its Home Health and Hospice customers to access more than 50,000 provider locations and health systems nationwide via the CommonWell Health Alliance, a nonprofit national trade association of health IT companies, and through CommonWell to Carequality, a national, consensus-built common interoperability framework. This represents an important step forward in bridging the gap between out-of-hospital care providers and the broader care ecosystem, solving for when providers lose visibility into their patients’ care when they enter a post-acute care setting.
SAN DIEGO-- -- Year-over-year revenue grows 12%, gross margin improves 100 basis points, operating profit up 15% MatrixCare contributes positively to revenue, gross margin, and profit ResMed well-positioned for the future Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com ResMed Inc. , a world-leading connected health company, today announced ...
ResMed today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes.
Now offers “tube-up” design options for nasal and nasal pillows mask wearers, providing even more flexibility and choice to help users sleep better in any position
HMEs can now see workflow insights, KPI tracking, and peer benchmarking on one auto-produced dashboard to enhance business decision-making
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Brand-agnostic solution helps HMEs provide timely PAP replacement supplies to sleep apnea patients, increases long-term adherence and improves satisfaction
ResMed (RMD) (RMD.AX) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software. Additional information regarding the investor meeting, including the specific time and webcast link for the presentations, will be made available approximately one week prior to the event and may be accessed by visiting http://investor.resmed.com. Presentations at the investor meeting will be transmitted by a live webcast, which may be accessed by visiting http://investor.resmed.com.
ResMed (NYSE: RMD, ASX: RMD), a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, today announced that is has completed the acquisition of HB Healthcare (HBH) to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. HBH, a fast-growing privately owned South Korean home medical equipment provider, serves both reimbursed and cash-pay customers of sleep and respiratory care devices.
- Home infusion therapy providers and HME pharmacies benefit from feature-rich functionality within a single software solution for all clinical, billing and reporting needs
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BLOOMINGTON, Minn., Feb. 27, 2019 -- MatrixCare announced today that it has entered into a National Pharmacy Integration and Electronic Medication Administration Record (eMAR).
MADISON, Wis., Feb. 21, 2019 /PRNewswire/ -- The vast majority of people with asthma may be using their inhalers incorrectly, potentially making their medicine less effective and increasing their risk of asthma attacks, according to new research published in The Journal of Allergy and Clinical Immunology: In practice by digital therapeutics company Propeller Health, in partnership with the University of Colorado School of Medicine and Children's Hospital Colorado. Many asthma medicines require that patients take two "puffs" of their inhaler to receive the prescribed dose.
ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. The settlement involves no payment or admission of liability by either side. “I am pleased we were able to resolve these disputes,” said ResMed CEO Mick Farrell.
Investorideas.com, a leading investor news resource covering technology and healthcare stocks releases a snapshot looking at how healthcare is changing in the digital age. Investorideas recently reported on how Digital Health technologies enabling out-of-hospital care and monitoring are forecast to grow by 30 percent and cross the $25 billion mark. In the article, Kamaljit Behera, Industry Analyst, Transformational Health, said, "In this highly digitized environment, artificial intelligence (AI) will permeate the life sciences ecosystem, and its use in healthcare IT (HIT) is likely to cross $1.7 billion by the end of 2019.
SAN DIEGO-- -- Year-over-year growth in revenue, gross margin, and operating profit Well-positioned for future growth through further penetration of untreated sleep apnea and expanding portfolio in respiratory care and Software as a Service Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. EST today at http://investor.resmed.com ResMed Inc. , a world-leading connected health ...
ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the United States, with a newly designed nasal cradle cushion that sits just under the wearer’s nose. The nasal cradle cushion – ResMed’s first – is designed to reduce facial markings and irritation. AirFit N30i is also convenient for equipment providers and sleep labs – it fits 96 percent of PAP users with just two frame sizes and four cushion sizes.
NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ResMed (NYSE: RMD, ASX: RMD), a leader in respiratory care medical devices and out-of-hospital care software, today announced that its premier portable oxygen concentrator, Mobi, is now widely available in the United States. Mobi offers an optimal balance of oxygen delivery, weight and battery life so that millions of people with chronic obstructive pulmonary disease (COPD) or other chronic diseases can enjoy ResMed-quality oxygen therapy wherever they go.
RADNOR, Pa., Jan. 7, 2019 /PRNewswire/ -- Safeguard Scientifics, Inc. (SFE) (Safeguard or the Company) today announced that its partner company, Propeller Health, has been acquired by ResMed (RMD) (RMD.AX) for $225 million in cash. Safeguard will receive total cash proceeds of $41.4 million, which excludes an amount of additional proceeds to be held in escrow, representing an approximate 3x cash-on-cash return and 34% IRR. "The closing of the Propeller Health acquisition by ResMed brings together two exceptional teams dedicated to improving respiratory medicine with digital technology.